Pharmaceutical

Oncternal stock crashes by 60% as it lays off staff and scraps trials

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.

Sep 14, 2024 - 04:00
Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Read the original article

Tags:

Previous Article

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Next Article

Cidara axes 30% of staff to focus on flu prevention drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Container Closure Integrity Testing (CCIT): How to get started with deterministic methods

Container Closure Integrity Testing (CCIT): How to get ...

Mar 29, 2023

STAT+: In ‘major milestone,’ FDA approves first cell therapy for solid tumors

STAT+: In ‘major milestone,’ FDA approves first cell th...

Feb 17, 2024

Opinion: Without a plan to fight superbugs, the Cancer Moonshot will never achieve liftoff

Opinion: Without a plan to fight superbugs, the Cancer ...

Aug 3, 2023